Cara Therapeutics Reports Second Quarter 2016 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cara Therapeutics (CARA) Misses Q2 EPS by 6c
August 4, 2016 4:36 PM EDTCara Therapeutics (NASDAQ: CARA) reported Q2 EPS of ($0.48), $0.06 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $79 thousand versus the consensus estimate of $130 thousand.
For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.
... More